Welcome to our dedicated page for Biocryst Pharmaceuticals news (Ticker: BCRX), a resource for investors and traders seeking the latest updates and insights on Biocryst Pharmaceuticals stock.
BioCryst Pharmaceuticals Inc (BCRX) is a biotechnology leader developing innovative therapies for rare diseases and infectious conditions through targeted enzyme inhibition. This news hub provides investors and healthcare professionals with timely updates on clinical developments, regulatory milestones, and strategic initiatives.
Access authoritative reporting on BCRX's pipeline progress, including updates on hereditary angioedema treatments and antiviral therapies. Our curated collection features earnings announcements, research breakthroughs, and partnership disclosures – all essential for tracking this biopharma innovator.
Key updates include FDA decisions, clinical trial results, and scientific publications. Bookmark this page for streamlined access to verified BioCryst news, eliminating the need to monitor multiple sources. Check regularly for developments impacting the company's position in enzyme inhibitor therapeutics and rare disease treatment markets.
BioCryst (Nasdaq: BCRX) announced on October 3, 2025 that its compensation committee granted inducement equity awards to eight newly hired employees.
The package includes 115,000 stock options and 91,450 restricted stock units (RSUs), granted effective October 1, 2025 under Nasdaq Listing Rule 5635(c)(4). Options carry an exercise price of $7.37 (closing price on the grant date), vest in four equal annual installments beginning one year after grant, and have a 10-year term. Awards are subject to the company’s Inducement Equity Incentive Plan and applicable award agreements.
BioCryst Pharmaceuticals (Nasdaq: BCRX) has completed the sale of its European ORLADEYO business to Neopharmed Gentili for $250 million upfront, with potential additional milestones of up to $14 million. The transaction represents a multiple of 5.4x last twelve months sales through June 2025.
Despite the European business divestiture, BioCryst maintains its 2025 revenue guidance of $580-600 million. The company plans to use the proceeds to retire its $199 million Pharmakon term loan. The deal allows BioCryst to focus on its core U.S. market while Neopharmed Gentili will lead European commercialization, retaining the existing European commercial team.
BioCryst Pharmaceuticals (Nasdaq: BCRX) has granted equity-based compensation to nine newly-hired employees as employment inducements. The compensation package includes:
- Stock options to purchase 36,700 shares at $8.29 per share (equal to closing price on grant date)
- Restricted stock units (RSUs) covering 71,400 shares of common stock
Both options and RSUs were granted on September 2, 2025, and will vest in four equal annual installments. The options have a 10-year term and were granted under BioCryst's Inducement Equity Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
BioCryst Pharmaceuticals (Nasdaq: BCRX) announced its upcoming presentation at the Cantor Global Healthcare Conference in New York. The presentation is scheduled for Thursday, September 4, 2025, at 9:45 a.m. ET. Investors can access both the live audio webcast and replay through the Investors & Media section of BioCryst's website.
BioCryst Pharmaceuticals (Nasdaq: BCRX) announced that Dr. Helen Thackray, Chief Research and Development Officer, will depart the company on September 1, 2025, transitioning to an advisory role through year-end. Dr. Thackray, who joined as a board member in 2019 and became R&D chief in 2021, was a finalist in the recent CEO succession process.
Under her leadership, BioCryst achieved significant milestones, including launching the KLK5 inhibitor BCX17725 for Netherton syndrome, advancing the avoralstat program for diabetic macular edema, and bringing the ORLADEYO pediatric program close to market approval. Dr. Thackray is departing to pursue a chief executive leadership opportunity elsewhere.
BioCryst Pharmaceuticals (Nasdaq: BCRX) announced the granting of stock options and restricted stock units (RSUs) to 10 newly-hired employees as employment inducements. The compensation committee approved options to purchase 36,700 shares and RSUs covering 89,750 shares of common stock.
The options were granted with an exercise price of $7.95 per share, matching BioCryst's closing price on August 1, 2025. Both options and RSUs will vest over four equal annual installments, starting one year from the grant date, with options having a 10-year term. These grants were made under BioCryst's Inducement Equity Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
BioCryst Pharmaceuticals (Nasdaq:BCRX) reported outstanding Q2 2025 financial results, marking the company's best quarter historically. ORLADEYO net revenue reached $156.8 million, up 45% year-over-year, with total revenues of $163.4 million. The company achieved an operating profit of $29.8 million (+239% y-o-y) and non-GAAP operating profit of $57.0 million.
Key highlights include record-breaking new patient prescriptions, increased prescriber base, and lower discontinuation rates. BioCryst made a $50 million debt paydown in July and plans to retire all remaining term debt using proceeds from the sale of its European ORLADEYO business. The company maintains its 2025 ORLADEYO revenue guidance of $580-600 million and expects positive cash flows for the full year.
The rare disease pipeline continues advancing with ORLADEYO granules for children (PDUFA date: December 12, 2025) and expected initial data from BCX17725 and avoralstat programs by year-end.BioCryst Pharmaceuticals (Nasdaq: BCRX) announced a significant leadership transition as CEO Jon Stonehouse plans to retire on December 31, 2025. Charlie Gayer, the company's current Chief Commercial Officer, will assume the role of president on August 1, 2025, and become CEO on January 1, 2026.
Gayer has been instrumental in the successful launch of ORLADEYO®, the company's oral prophylactic therapy for hereditary angioedema, which is expected to achieve peak sales of $1 billion. He also played a key role in the planned sale of BioCryst's European operations. Gayer joined BioCryst in 2015 and brings extensive experience from leadership roles at Talecris Biotherapeutics, Grifols, and GlaxoSmithKline.
BioCryst Pharmaceuticals (Nasdaq: BCRX) has scheduled its second quarter 2025 financial results announcement for Monday, August 4, 2025. The company will host a conference call and webcast at 8:30 a.m. ET to discuss the financial results and provide a corporate update.
Investors can access the live call by dialing 1-844-481-2942 (domestic) or 1-412-317-1866 (international). A live webcast and replay will be available in the investors section at www.biocryst.com.
BioCryst Pharmaceuticals (Nasdaq: BCRX) announced its participation in the 2025 US HAEA National Summit in Baltimore from July 10-13, 2025. The company will present three research posters focusing on HAE treatments, including patient perspectives, treatment burden on pediatric patients under 12 and their caregivers, and attack rates in pediatric patients using prophylactic berotralstat.
CEO Jon Stonehouse emphasized the company's decade-long commitment to the HAE patient community and highlighted BioCryst's achievement in developing the first oral, once-daily prophylactic therapy for HAE in adults and adolescents. Stonehouse will deliver a corporate presentation during the summit.
FAQ
What is the current stock price of Biocryst Pharmaceuticals (BCRX)?
What is the market cap of Biocryst Pharmaceuticals (BCRX)?
